Financials in USD. Standardized financial statements.
A compact view of how VYNE Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $570,000 | $501,000 | $424,000 | $477,000 | $931,000 | $20.99M | $443,000 | $10.64M | $4.58M | $674,000 |
| Revenue Growth? | +13.8% | +18.2% | -11.1% | -48.8% | -95.6% | +4638.8% | -95.8% | +132.2% | +579.8% | 0.0% |
| Cost of Revenue? | $23,000 | $0 | $0 | $0 | $0 | $1.39M | $350,000 | $0 | $0 | $0 |
| Gross Profit? | $547,000 | $501,000 | $424,000 | $477,000 | $931,000 | $19.60M | $93,000 | $10.64M | $4.58M | $674,000 |
| Gross Margin? | +96.0% | +100.0% | +100.0% | +100.0% | +100.0% | +93.4% | +21.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $30.30M | $44.14M | $29.68M | $34.77M | $39.84M | -$232.94M | $76.24M | $65.17M | $34.17M | $15.01M |
| Operating Income? | -$29.75M | -$43.64M | -$29.26M | -$34.30M | -$38.91M | $252.55M | -$76.24M | -$54.53M | -$29.59M | -$14.33M |
| EBITDA? | -$26.73M | -$43.63M | -$29.26M | -$34.22M | -$38.80M | -$251.09M | -$94.08M | -$54.53M | -$29.59M | -$14.33M |
| Income Before Tax | -$26.73M | -$39.80M | -$27.87M | -$33.93M | -$43.76M | -$255.83M | -$73.70M | -$51.45M | -$29.08M | -$14.07M |
| Income Tax Expense | $4,000 | $4,000 | $0 | $13,000 | $447,999 | -$258,000 | -$3.24M | $0 | -$8,000 | $0 |
| Net Income? | -$26.48M | -$39.83M | -$28.45M | -$23.21M | -$73.33M | -$255.57M | -$70.46M | -$51.45M | -$29.08M | -$14.07M |
| EPS? | $-0.62 | $-0.94 | $-2.77 | $-10.65 | $-25.65 | $-141.90 | $-149.48 | $-170.94 | $-101.65 | $-46.49 |
| Diluted EPS? | $-0.62 | $-0.94 | $-2.77 | $-10.65 | $-25.65 | $-141.90 | $-149.48 | $-170.94 | $-101.65 | $-46.49 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality